FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953394580> ?p ?o ?g. }

• W2953394580 endingPage "e1002835" @default.
• W2953394580 startingPage "e1002835" @default.
• W2953394580 abstract "Mass azithromycin distributions have been shown to reduce mortality in preschool children, although the factors mediating this mortality reduction are not clear. This study was performed to determine whether mass distribution of azithromycin, which has modest antimalarial activity, reduces the community burden of malaria.In a cluster-randomized trial conducted from 23 November 2014 until 31 July 2017, 30 rural communities in Niger were randomized to 2 years of biannual mass distributions of either azithromycin (20 mg/kg oral suspension) or placebo to children aged 1 to 59 months. Participants, field staff, and investigators were masked to treatment allocation. The primary malaria outcome was the community prevalence of parasitemia on thick blood smear, assessed in a random sample of children from each community at study visits 12 and 24 months after randomization. Analyses were performed in an intention-to-treat fashion. At the baseline visit, a total of 1,695 children were enumerated in the 15 azithromycin communities, and 3,029 children were enumerated in the 15 placebo communities. No communities were lost to follow-up. The mean prevalence of malaria parasitemia at baseline was 8.9% (95% CI 5.1%-15.7%; 52 of 552 children across all communities) in the azithromycin-treated group and 6.7% (95% CI 4.0%-12.6%; 36 of 542 children across all communities) in the placebo-treated group. In the prespecified primary analysis, parasitemia was lower in the azithromycin-treated group at month 12 (mean prevalence 8.8%, 95% CI 5.1%-14.3%; 51 of 551 children across all communities) and month 24 (mean 3.5%, 95% CI 1.9%-5.5%; 21 of 567 children across all communities) than it was in the placebo-treated group at month 12 (mean 15.3%, 95% CI 10.8%-20.6%; 81 of 548 children across all communities) and month 24 (mean 4.8%, 95% CI 3.3%-6.4%; 28 of 592 children across all communities) (P = 0.02). Communities treated with azithromycin had approximately half the odds of parasitemia compared to those treated with placebo (odds ratio [OR] 0.54, 95% CI 0.30 to 0.97). Parasite density was lower in the azithromycin group than the placebo group at 12 and 24 months (square root-transformed outcome; density estimates were 7,540 parasites/μl lower [95% CI -350 to -12,550 parasites/μl; P = 0.02] at a mean parasite density of 17,000, as was observed in the placebo arm). No significant difference in hemoglobin was observed between the 2 treatment groups at 12 and 24 months (mean 0.34 g/dL higher in the azithromycin arm, 95% CI -0.06 to 0.75 g/dL; P = 0.10). No serious adverse events were reported in either group, and among children aged 1 to 5 months, the most commonly reported nonserious adverse events (i.e., diarrhea, vomiting, and rash) were less common in the azithromycin-treated communities. Limitations of the trial include the timing of the treatments and monitoring visits, both of which took place before the peak malaria season, as well as the uncertain generalizability to areas with different malaria transmission dynamics.Mass azithromycin distributions were associated with a reduced prevalence of malaria parasitemia in this trial, suggesting one possible mechanism for the mortality benefit observed with this intervention.The trial was registered on ClinicalTrials.gov (NCT02048007)." @default.
• W2953394580 created "2019-07-12" @default.
• W2953394580 creator A5006338001 @default.
• W2953394580 creator A5024510654 @default.
• W2953394580 creator A5033288392 @default.
• W2953394580 creator A5038025520 @default.
• W2953394580 creator A5053637474 @default.
• W2953394580 creator A5058005277 @default.
• W2953394580 creator A5068761394 @default.
• W2953394580 creator A5069369290 @default.
• W2953394580 creator A5075952432 @default.
• W2953394580 creator A5077631479 @default.
• W2953394580 creator A5080095497 @default.
• W2953394580 creator A5088225687 @default.
• W2953394580 creator A5089206390 @default.
• W2953394580 date "2019-06-25" @default.
• W2953394580 modified "2023-09-24" @default.
• W2953394580 title "Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial" @default.
• W2953394580 cites W1985253152 @default.
• W2953394580 cites W1996122690 @default.
• W2953394580 cites W2007852671 @default.
• W2953394580 cites W2017261836 @default.
• W2953394580 cites W2053781571 @default.
• W2953394580 cites W2061525364 @default.
• W2953394580 cites W2096572034 @default.
• W2953394580 cites W2096994469 @default.
• W2953394580 cites W2107760001 @default.
• W2953394580 cites W2132553165 @default.
• W2953394580 cites W2139477092 @default.
• W2953394580 cites W2144175940 @default.
• W2953394580 cites W2188380706 @default.
• W2953394580 cites W2286507655 @default.
• W2953394580 cites W2403369344 @default.
• W2953394580 cites W2460284770 @default.
• W2953394580 cites W2609152998 @default.
• W2953394580 cites W2741872984 @default.
• W2953394580 cites W2766238630 @default.
• W2953394580 cites W2767125253 @default.
• W2953394580 cites W2801239041 @default.
• W2953394580 cites W2901408395 @default.
• W2953394580 cites W2905587610 @default.
• W2953394580 cites W2913974122 @default.
• W2953394580 doi "https://doi.org/10.1371/journal.pmed.1002835" @default.
• W2953394580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6592520" @default.
• W2953394580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31237871" @default.
• W2953394580 hasPublicationYear "2019" @default.
• W2953394580 type Work @default.
• W2953394580 sameAs 2953394580 @default.
• W2953394580 citedByCount "31" @default.
• W2953394580 countsByYear W29533945802019 @default.
• W2953394580 countsByYear W29533945802020 @default.
• W2953394580 countsByYear W29533945802021 @default.
• W2953394580 countsByYear W29533945802022 @default.
• W2953394580 countsByYear W29533945802023 @default.
• W2953394580 crossrefType "journal-article" @default.
• W2953394580 hasAuthorship W2953394580A5006338001 @default.
• W2953394580 hasAuthorship W2953394580A5024510654 @default.
• W2953394580 hasAuthorship W2953394580A5033288392 @default.
• W2953394580 hasAuthorship W2953394580A5038025520 @default.
• W2953394580 hasAuthorship W2953394580A5053637474 @default.
• W2953394580 hasAuthorship W2953394580A5058005277 @default.
• W2953394580 hasAuthorship W2953394580A5068761394 @default.
• W2953394580 hasAuthorship W2953394580A5069369290 @default.
• W2953394580 hasAuthorship W2953394580A5075952432 @default.
• W2953394580 hasAuthorship W2953394580A5077631479 @default.
• W2953394580 hasAuthorship W2953394580A5080095497 @default.
• W2953394580 hasAuthorship W2953394580A5088225687 @default.
• W2953394580 hasAuthorship W2953394580A5089206390 @default.
• W2953394580 hasBestOaLocation W29533945801 @default.
• W2953394580 hasConcept C126322002 @default.
• W2953394580 hasConcept C142724271 @default.
• W2953394580 hasConcept C144024400 @default.
• W2953394580 hasConcept C149923435 @default.
• W2953394580 hasConcept C168563851 @default.
• W2953394580 hasConcept C176400912 @default.
• W2953394580 hasConcept C187212893 @default.
• W2953394580 hasConcept C203014093 @default.
• W2953394580 hasConcept C204243189 @default.
• W2953394580 hasConcept C204787440 @default.
• W2953394580 hasConcept C27081682 @default.
• W2953394580 hasConcept C2775867548 @default.
• W2953394580 hasConcept C2778048844 @default.
• W2953394580 hasConcept C2778371730 @default.
• W2953394580 hasConcept C2778907293 @default.
• W2953394580 hasConcept C501593827 @default.
• W2953394580 hasConcept C71924100 @default.
• W2953394580 hasConcept C86803240 @default.
• W2953394580 hasConcept C89423630 @default.
• W2953394580 hasConceptScore W2953394580C126322002 @default.
• W2953394580 hasConceptScore W2953394580C142724271 @default.
• W2953394580 hasConceptScore W2953394580C144024400 @default.
• W2953394580 hasConceptScore W2953394580C149923435 @default.
• W2953394580 hasConceptScore W2953394580C168563851 @default.
• W2953394580 hasConceptScore W2953394580C176400912 @default.
• W2953394580 hasConceptScore W2953394580C187212893 @default.
• W2953394580 hasConceptScore W2953394580C203014093 @default.
• W2953394580 hasConceptScore W2953394580C204243189 @default.
• W2953394580 hasConceptScore W2953394580C204787440 @default.

• next